ERBB2 and hydrops fetalis: In a study of 500 HER2 + patients treated with trastuzumab, 27% of patients were diagnosed with cardiotoxicity (symptomatic HF or asymptomatic drop in LVEF) however this only led to treatment discontinuation in 5% of patients.